https://www.selleckchem.com/pr....oducts/dir-cy7-dic18
2-51.2%) in Cohort A and 0% in Cohort B (95% CI0-41.0%). WES revealed more frequent alterations in TP53 (p 0.05, q 0.05) in patients without clinical benefit (disease control for 24weeks) which was not significant after multiple hypothesis correction. Eribulin-HP had manageable toxicity and modest clinical activity in patients without prior pertuzumab exposure. This study provides a preliminary landscape of somatic alterations in this patient cohort. Our data add to the literature on how genomic alterations may pred
Like
Comment
Share
